The earnings call presented a strong performance with significant growth in organic revenue and innovation, supported by a robust Farm Animal segment and improved leverage ratios. However, the impact of tariffs and increased operating expenses, along with a decline in gross margin, presented challenges. The positive aspects of the call, including record growth and innovation success, outweigh the lowlights.

Company Guidance

During Elanco Animal Health's second quarter 2025 earnings call, the company reported an 8% organic constant currency revenue growth, surpassing expectations for revenue, adjusted EBITDA, and adjusted EPS. The U.S. Pet Health segment led with an 11% growth, driven by both price and volume, marking eight consecutive quarters of underlying growth. Innovation was a key driver, generating $420 million in first-half revenue, prompting the company to raise full-year expectations by $60 million to a range of $720 million to $800 million. Elanco improved its net leverage ratio to 4.0x, thanks to strong cash generation and working capital discipline, and revised its year-end net leverage target to 3.8x to 4.1x. Despite potential tariff impacts, the company maintained a 2025 guidance of 5% to 6% organic constant currency growth, $850 million to $890 million in adjusted EBITDA, and adjusted EPS between $0.85 and $0.91, showcasing confidence in its ability to navigate external uncertainties while executing its long-term growth strategy.

Record Organic Growth

Elanco achieved 8% organic constant currency revenue growth, driven by U.S. Pet Health up 11%, marking the 8th consecutive quarter of underlying growth.

Innovation Revenue Exceeds Expectations

Innovation achieved $420 million in first half revenue, with full-year expectations raised by $60 million to $720 million to $800 million.

Improved Leverage Ratio

Net leverage ratio improved to 4.0x, with expectations to reach 3.8 to 4.1x by year-end, driven by strong cash generation and operational performance.

Strong Performance in Farm Animal Segment

U.S. Farm Animal business up 5%, driven by Experior with rapid adoption and positive market leadership in beef, poultry, and swine.

Expanded Global Reach with Product Approvals

Zenrelia received approval in the EU and Switzerland, with strong launches in Brazil, Canada, and Japan, expanding Elanco's global footprint.

Elanco Animal Health (ELAN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ELAN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.13 / -	0.13	―	―	―
Aug 07, 2025	2025 (Q2)	0.20 / 0.26	0.3	-13.33% (-0.04)
May 07, 2025	2025 (Q1)	0.31 / 0.37	0.34	8.82% (+0.03)
Feb 25, 2025	2024 (Q4)	0.15 / 0.14	0.08	75.00% (+0.06)
Nov 07, 2024	2024 (Q3)	0.12 / 0.13	0.18	-27.78% (-0.05)
Aug 08, 2024	2024 (Q2)	0.24 / 0.30	0.18	66.67% (+0.12)
May 08, 2024	2024 (Q1)	0.27 / 0.34	0.45	-24.44% (-0.11)
Feb 26, 2024	2023 (Q4)	0.10 / 0.08	0.19	-57.89% (-0.11)
Nov 07, 2023	2023 (Q3)	0.13 / 0.18	0.2	-10.00% (-0.02)
Aug 07, 2023	2023 (Q2)	0.05 / 0.18	0.36	-50.00% (-0.18)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ELAN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$13.95	$16.48	+18.14%
May 07, 2025	$9.51	$12.01	+26.29%
Feb 25, 2025	$11.11	$10.70	-3.69%
Nov 07, 2024	$12.86	$14.50	+12.75%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.